Verona Pharma Plc - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Verona Pharma Plc. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Verona Pharma Plc. The Group's principal activity is researching and developing drugs for the treatment of allergic rhinitis and other chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease as well as chronic inflammatory diseases. The Group's lead drug compound, RPL554, is a long acting inhibitor of both phosphodiesterase 3 and phosphodiesterase 4 enzymes, two enzymes known to be of importance in the development and progression of immunological respiratory diseases, particularly rhinitis (hay fever) and asthma.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report